In a first set of experiments, we performed pMHCI-tetramer-based enrichment to screen a cohort of 47 therapy-naïve HCC patients (Supplementary Table 1) for the presence of circulating TAA-specific CD8+ T cells targeting the HLA-A*02-restricted epitopes NY-ESO-1157, MAGE-A3271, Glypican-3521 and AFP47, and the HLA-A*03-restricted epitopes MAGE-A196, and Glypican-3519. The gene discussed is CD8A; the disease is hepatocellular carcinoma.